About lineage cell therapeutics - LCTX
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The company's pipeline consists of seven allogeneic cell transplant therapy programs spanning clinical to research stages, targeting a range of conditions including dry-AMD, spinal cord injuries, auditory neuropathy, Type 1 Diabetes, and vision loss, with several programs supported by strategic partnerships with Roche, Genentech, William Demant Invest, and Factor Biosciences. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.
LCTX At a Glance
Lineage Cell Therapeutics, Inc.
2173 Salk Avenue
Carlsbad, California 92008-7354
| Phone | 1-442-287-8990 | Revenue | 14.56M | |
| Industry | Biotechnology | Net Income | -63,533,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 53.237% | |
| Fiscal Year-end | 12 / 2026 | Employees | 77 | |
| View SEC Filings |
LCTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 26.401 |
| Price to Book Ratio | 9.114 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -15.642 |
| Enterprise Value to Sales | 22.652 |
| Total Debt to Enterprise Value | 0.007 |
LCTX Efficiency
| Revenue/Employee | 189,038.961 |
| Income Per Employee | -825,103.896 |
| Receivables Turnover | 9.319 |
| Total Asset Turnover | 0.129 |
LCTX Liquidity
| Current Ratio | 5.204 |
| Quick Ratio | 5.204 |
| Cash Ratio | 4.907 |
LCTX Profitability
| Gross Margin | 94.195 |
| Operating Margin | -149.622 |
| Pretax Margin | -471.606 |
| Net Margin | -436.473 |
| Return on Assets | -56.273 |
| Return on Equity | -103.365 |
| Return on Total Capital | -135.269 |
| Return on Invested Capital | -100.96 |
LCTX Capital Structure
| Total Debt to Total Equity | 5.43 |
| Total Debt to Total Capital | 5.15 |
| Total Debt to Total Assets | 2.149 |
| Long-Term Debt to Equity | 3.515 |
| Long-Term Debt to Total Capital | 3.334 |